Sobi emphasises commitment to haemophilia community at WFH 2018 World Congress
Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies. Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) will present data at the World Federation of Hemophilia (WFH) 2018 World Congress, in Glasgow, Scotland, 20-24 May, demonstrating the company’s ongoing commitment to transforming the standard of care for people with haemophilia. Sobi will present real-world data demonstrating improvements in quality-of-life measures, including physical activity and joint pain,